Adlai Nortye: 4.56M Shares Reported (2.9%)

Adlai Nortye Ltd. files a Schedule 13G/A reporting beneficial ownership of 4,561,077 ordinary shares.

Rhea-AI Filing Summary

Adlai Nortye Ltd. files a Schedule 13G/A reporting beneficial ownership of 4,561,077 ordinary shares. The filing states this holding represents 2.9% of the issuer's ordinary shares based on April 10, 2026 outstanding counts. The calculation references 142,241,572 Class A and 16,990,000 Class B ordinary shares outstanding as of that date, and attributes sole voting and dispositive power over the 4,561,077 shares to JIN YIN (BVI) LIMITED with a chain of indirect ownership through related entities and Shijun Feng.

Insights

Corporate Governance Analyst

Filing documents a passive beneficial ownership stake of 2.9% held through related entities.

The statement lists 4,561,077 shares under the sole voting and dispositive power of JIN YIN (BVI) LIMITED, with ownership traced through Shanghai Gaopei Duwei Biotechnology Co., Ltd., Hangzhou Jingyin Investment Partnership, Hangzhou Jingfeng Investment Management Company, and ultimately to Shijun Feng. The cover comments tie the percentage to the issuer's reported outstanding share counts as of April 10, 2026.

Filing certifies the holdings were not acquired to influence control; cash‑flow treatment is not stated. Subsequent filings may disclose changes in position or voting arrangements.

Securities Compliance Specialist

Schedule 13G/A structure and attribution appear consistent with passive reporting and group beneficial-ownership rules.

The filing identifies the direct holder and describes the ownership chain that may cause attribution to affiliates and to Shijun Feng. It includes a signed certification asserting the shares are not held to change control. The statement references specific outstanding share counts used for the 2.9% calculation.

Material compliance items to watch in future filings include any amendment converting this to an active Schedule 13D or changes in sole voting/dispositive power.

Key Figures

Reported shares beneficially owned: 4,561,077 shares Reported ownership percentage: 2.9% Class A outstanding: 142,241,572 shares +1 more

4 metrics

Reported shares beneficially owned 4,561,077 shares Sole voting/dispositive power attributed to JIN YIN (BVI) LIMITED

Reported ownership percentage 2.9% Calculated using outstanding shares as of April 10, 2026

Class A outstanding 142,241,572 shares As of April 10, 2026

Class B outstanding 16,990,000 shares As of April 10, 2026

Key Terms

beneficially owned, sole dispositive power, Schedule 13G/A

3 terms

beneficially owned regulatory

"Representing 4,561,077 Class A ordinary shares of the Issuer held by JIN YIN (BVI) LIMITED"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

sole dispositive power regulatory

"Sole Dispositive Power 4,561,077.00"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

Schedule 13G/A regulatory

"Item 1. Name of issuer: Adlai Nortye Ltd."

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake does ANL Schedule 13G/A report for JIN YIN (BVI) LIMITED?

The filing reports 4,561,077 shares, representing 2.9% of the issuer's ordinary shares using the outstanding counts as of April 10, 2026.

How was the 2.9% ownership percentage calculated in the ANL filing?

The percentage is based on 142,241,572 Class A and 16,990,000 Class B ordinary shares outstanding as of April 10, 2026, as cited in the filing.

Who holds voting and dispositive power over the reported ANL shares?

The filing states JIN YIN (BVI) LIMITED has sole voting and sole dispositive power over the 4,561,077 shares reported on the cover pages.

Does the Schedule 13G/A indicate an intent to influence control of ANL?

No. The certifications state the securities "were not acquired and are not held for the purpose of or with the effect of changing or influencing the control" of the issuer.

Which entities are in the ownership chain for the ANL holdings?

The filing lists an ownership chain: JIN YIN (BVI) LIMITED owned by Shanghai Gaopei Duwei Biotechnology Co., Ltd., linked to Hangzhou Jingyin Investment Partnership, Hangzhou Jingfeng Investment Management Company, and ultimately Shijun Feng.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/14/2026 - 09:30 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Adlai Nortye Ltd.

(Name of Issuer)

Ordinary shares, par value US$0.0001 per share

(Title of Class of Securities)

00704R109

(CUSIP Number)

12/31/2023

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 00704R109

1

Names of Reporting Persons

JIN YIN (BVI) LIMITED

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

VIRGIN ISLANDS, BRITISH

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 4,561,077.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 4,561,077.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

4,561,077.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

2.9 %

12

Type of Reporting Person (See Instructions)

CO

Comment for Type of Reporting Person: (1) Representing 4,561,077 Class A ordinary shares of the Issuer held by JIN YIN (BVI) LIMITED. (2) This percentage is calculated based on a total of (i) 142,241,572 Class A ordinary shares and 16,990,000 Class B ordinary shares outstanding of the Issuer as of April 10th, 2026 as reported in the Issuer's annual report on Form 20-F filed on the same date.

SCHEDULE 13G

CUSIP Number(s): 00704R109

1

Names of Reporting Persons

Shanghai Gaopei Duwei Biotechnology Co., Ltd.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CHINA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 4,561,077.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 4,561,077.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

4,561,077.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

2.9 %

12

Type of Reporting Person (See Instructions)

CO

Comment for Type of Reporting Person: (3) Representing 4,561,077 Class A ordinary shares of the Issuer held by JIN YIN (BVI) LIMITED. Shanghai Gaopei Duwei Biotechnology Co., Ltd. holds 100.0% equity interest of JIN YIN (BVI) LIMITED.

SCHEDULE 13G

CUSIP Number(s): 00704R109

1

Names of Reporting Persons

Hangzhou Jingyin Investment Partnership (Limited Partnership)

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CHINA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 4,561,077.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 4,561,077.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

4,561,077.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

2.9 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: (4) Representing 4,561,077 Class A ordinary shares of the Issuer held by JIN YIN (BVI) LIMITED. Shanghai Gaopei Duwei Biotechnology Co., Ltd. holds 100.0% equity interest of JIN YIN (BVI) LIMITED. Hangzhou Jingyin Investment Partnership (Limited Partnership) holds 99.0% equity interest of Shanghai Gaopei Duwei Biotechnology Co., Ltd.

SCHEDULE 13G

CUSIP Number(s): 00704R109

1

Names of Reporting Persons

Hangzhou Jingfeng Investment Management Company

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CHINA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 4,561,077.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 4,561,077.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

4,561,077.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

2.9 %

12

Type of Reporting Person (See Instructions)

CO

Comment for Type of Reporting Person: (5) Representing 4,561,077 Class A ordinary shares of the Issuer held by JIN YIN (BVI) LIMITED. Shanghai Gaopei Duwei Biotechnology Co., Ltd. holds 100.0% equity interest of JIN YIN (BVI) LIMITED. Shanghai Gaopei Duwei Biotechnology Co., Ltd. holds 100.0% equity interest of JIN YIN (BVI) LIMITED. Hangzhou Jingyin Investment Partnership (Limited Partnership) holds 99.0% equity interest of Shanghai Gaopei Duwei Biotechnology Co., Ltd. Hangzhou Jingfeng Investment Management Company is the general partner of Hangzhou Jingyin Investment Partnership (Limited Partnership), and may be deemed to beneficially own the ordinary shares beneficially owned by Hangzhou Jingyin Investment Partnership (Limited Partnership).

SCHEDULE 13G

CUSIP Number(s): 00704R109

1

Names of Reporting Persons

Shijun Feng

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CHINA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 4,561,077.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 4,561,077.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

4,561,077.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

2.9 %

12

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person: (6) Representing 4,561,077 Class A ordinary shares of the Issuer held by JIN YIN (BVI) LIMITED. Shanghai Gaopei Duwei Biotechnology Co., Ltd. holds 100.0% equity interest of JIN YIN (BVI) LIMITED. Shanghai Gaopei Duwei Biotechnology Co., Ltd. holds 100.0% equity interest of JIN YIN (BVI) LIMITED. Hangzhou Jingyin Investment Partnership (Limited Partnership) holds 99.0% equity interest of Shanghai Gaopei Duwei Biotechnology Co., Ltd. Hangzhou Jingfeng Investment Management Company is the general partner of Hangzhou Jingyin Investment Partnership (Limited Partnership), and may be deemed to beneficially own the ordinary shares beneficially owned by Hangzhou Jingyin Investment Partnership (Limited Partnership). Shijun Feng holds 100.0% equity interest of Hangzhou Jingfeng Investment Management Company.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Adlai Nortye Ltd.
(b)	Address of issuer's principal executive offices: c/o PO Box 309, Ugland House, Grand Cayman KY1-1104, Cayman Islands
Item 2.
(a)	Name of person filing: (i) JIN YIN (BVI) LIMITED (ii) Shanghai Gaopei Duwei Biotechnology Co., Ltd. (iii) Hangzhou Jingyin Investment Partnership (Limited Partnership) (iv) Hangzhou Jingfeng Investment Management Company (v) Shijun Feng
(b)	Address or principal business office or, if none, residence: JIN YIN (BVI) LIMITED Craigmuir Chambers, Road Town, Tortola, VG 1110, British Virgin Islands Shanghai Gaopei Duwei Biotechnology Co., Ltd. Rm 401, Block 2, Building 2, Feicui Hai'an, Wangjiang Street, Shangcheng District, Hangzhou, Zhejiang Province, the People's Republic of China Hangzhou Jingyin Investment Partnership (Limited Partnership) Rm 401, Block 2, Building 2, Feicui Hai'an, Wangjiang Street, Shangcheng District, Hangzhou, Zhejiang Province, the People's Republic of China Hangzhou Jingfeng Investment Management Company Rm 401, Block 2, Building 2, Feicui Hai'an, Wangjiang Street, Shangcheng District, Hangzhou, Zhejiang Province, the People's Republic of China Shijun Feng Rm 401, Block 2, Building 2, Feicui Hai'an, Wangjiang Street, Shangcheng District, Hangzhou, Zhejiang Province, the People's Republic of China
(c)	Citizenship: JIN YIN (BVI) LIMITED British Virgin Islands Shanghai Gaopei Duwei Biotechnology Co., Ltd. The People's Republic of China Hangzhou Jingyin Investment Partnership (Limited Partnership) The People's Republic of China Hangzhou Jingfeng Investment Management Company The People's Republic of China Shijun Feng The People's Republic of China
(d)	Title of class of securities: Ordinary shares, par value US$0.0001 per share
(e)	CUSIP No.: 00704R109
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See Item 9 of each cover page.
(b)	Percent of class: See Item 11 of each cover page. The calculation is based on a total of (i) 142,241,572 Class A ordinary shares and 16,990,000 Class B ordinary shares outstanding of the Issuer as of April 10th, 2026 as reported in the Issuer's annual report on Form 20-F filed on the same date.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See Item 5 of each cover page.
	(ii) Shared power to vote or to direct the vote: See Item 6 of each cover page.
	(iii) Sole power to dispose or to direct the disposition of: See Item 7 of each cover page.
	(iv) Shared power to dispose or to direct the disposition of: See Item 8 of each cover page. JIN YIN (BVI) LIMITED is the direct holder of the securities covered by this statement. JIN YIN (BVI) LIMITED is wolly owned by Shanghai Gaopei Duwei Biotechnology Co., Ltd.. Shanghai Gaopei Duwei Biotechnology Co., Ltd. holds 100.0% equity interest of JIN YIN (BVI) LIMITED. Hangzhou Jingyin Investment Partnership (Limited Partnership) holds 99.0% equity interest of Shanghai Gaopei Duwei Biotechnology Co., Ltd. Hangzhou Jingfeng Investment Management Company is the general partner of Hangzhou Jingyin Investment Partnership (Limited Partnership), and may be deemed to beneficially own the ordinary shares beneficially owned by Hangzhou Jingyin Investment Partnership (Limited Partnership). Shijun Feng holds 100.0% equity interest of Hangzhou Jingfeng Investment Management Company. Accoridngly, Shijun Feng may be deemed as the beneficial owner of the ordinary shares of the Issuer held by JIN YIN (BVI) LIMITED.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.	Certifications:
	By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the Issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

JIN YIN (BVI) LIMITED

Signature:	/s/ Shijun Feng
Name/Title:	Shijun Feng/Director
Date:	05/14/2026

Shanghai Gaopei Duwei Biotechnology Co., Ltd.

Signature:	/s/ Shijun Feng
Name/Title:	Shijun Feng/Director
Date:	05/14/2026

Hangzhou Jingyin Investment Partnership (Limited Partnership)

Signature:	/s/ Yue'ai Jiang
Name/Title:	Yue'ai Jiang/Authorized Person
Date:	05/14/2026

Hangzhou Jingfeng Investment Management Company

Signature:	/s/ Shijun Feng
Name/Title:	Shijun Feng/Director
Date:	05/14/2026

Shijun Feng

Signature:	/s/ Shijun Feng
Name/Title:	Shijun Feng
Date:	05/14/2026

Exhibit Information

99.1 Joint Filing Agreement